US20060127271A1 - Non-thermal disinfection of biological fluids using non-thermal plasma - Google Patents

Abstract

A method and apparatus are provided for at least partially disinfecting biological fluid of a mammal, which comprises pathogens. The method includes contacting a non-thermal plasma with the biological fluid to kill at least a portion of the pathogens within the biological fluid, and filtering toxins from at least some components of the biological fluid.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
• This application is a continuation of U.S. application Ser. No. 10/426,605, Filed Apr. 30, 2003 and entitled “NON-THERMAL DISINFECTION OF BIOLOGICAL FLUIDS USING NON-THERMAL PLASMA;” which claims the benefit of U.S. Provisional Application No. 60/377,130, filed Apr. 30, 2002, and is a continuation-in-part of U.S. application Ser. No. 10/364,599, filed Feb. 11, 2003 and entitled “METHOD AND APPARATUS FOR NON-THERMAL PASTEURIZATION OF LIVING-MAMMAL INSTILLABLE LIQUIDS;” which is a continuation-in-part of U.S. application Ser. No. 09/850,284, filed May 7, 2001 and entitled “METHOD AND APPARATUS FOR NON-THERMAL PASTEURIZATION.”
FIELD OF THE INVENTION
• The present invention relates to a method and apparatus for disinfection of biological fluids to cleanse the fluids of pathogenic microorganisms.
BACKGROUND OF THE INVENTION
• The phenomenon of bacterial resistance through micro-evolutionary change has been well documented. Substantial concerns over the degrading effectiveness of classic broad spectrum antibiotics, such as penicillin and its analogues, as the microbes have adapted new protection mechanisms, has led to medical protocols that attempt to minimize their usage. The goal is to delay the time when larger segments of the population may find the effectiveness of critically needed antibiotics compromised for their needs. To delay this problem, such powerful anti-microbial agents as Vancomycin are prescribed only under the most stringent use protocols. In addition, there are few pharmacological compounds that have been found to be effective for treatment of viruses, and the few that exist are very strain-specific.
• The pharmaceutical industry is desperately seeking new ways to battle infection. The myriad attempts to develop improved types of antibotics and anti-viral agents include mechanisms ranging from various innovative chemical inactivation mechanisms, gene-based techniques of drug production, and tailored anti-infective medications for individual patients. What all of these approaches have in common is that they are chemical: drugs that are ingested and then act biochemically on the host. The disadvantage is that, while the pathogens may be destroyed, the patient may also be compromised or worse, due to drug toxicity.
• A further problem is that, in general for a severe systemic infection, there still exist antibiotic drugs that can effectively destroy bacterial pathogens. However, what often kills the patient are the toxic poisons that are released by the bacteria as they are lysed (destroyed) due to either immune system action or antibiotic effects. There are two categories of such substances: endotoxins, lipopolysaccharides that are associated with the cellular walls of gram-negative bacteria, and exotoxins, soluble proteins which are diffusible and may act at different sites from the bacterial invasion as some of the most potent poisons known, comparable to strychnine and snake venom. It may help the patient very little to destroy a bacterium that leaves a parting gift of poison for the host as it dies. A treatment is needed that has the potential to both destroy bacteria in biological fluids such as blood, and also allow toxins to be filtered out of the blood before they can injure the patient. This phenomenon is applicable to both humans and animals.
• Various methods of non-chemical purification of biological fluids, medicines, vaccines, etc., have been proposed to destroy or inactivate pathogens, including bacteria, viruses, and fungi, in the liquids. These methods typically generate heat during the purification process and may introduce impurities depending on the process. This heat can easily damage the active ingredients or critical live tissues that perform the essential functions of the fluids. In the case of biological fluids, if these tissues are thermally processed, they may become non-functional, as in the case of some clotting compounds, or vital living cells such as erythrocytes (red blood cells, RBC) or leukocytes (white blood cells, WBC) may be altered or damaged in ways that both mar instant function or compromise cellular stability, hardiness, or reproduction. When treating delicate biological fluids such as blood, these processes have had marginal success because blood functions properly in a very narrow temperature range around the normal 37 degrees C. (nominally 98.6 degrees F.).
• Blood that is drawn from donors and banked for transfusion currently must go through multiple exhaustive steps to ensure safety for use, and there are large volumes of scarce blood and plasma that must be destroyed when they are found to be contaminated. A pasteurization technology that is able to cycle fluids such as blood through an apparatus outside the body to destroy the bacterial infection, and then filter out the toxins released in the process, and permit blood or plasma to be safely used rather than wasted will provide significant benefit to the health care system. Such a safe and efficacious technology should also permit cost-saving protocol changes in the collection and handling of biological fluids such as blood.
• A number of minimal thermal processes have been developed for some of these applications, including ultra-filtration, ozonation, pulsed ultraviolet light, irradiation, high hydrostatic pressure (HHP) and pulsed electric field (PEF) discharge.
• PEF discharge has been shown to be very effective for killing bacteria within medically useful liquids that are not subject to degradation, such as vaccines, medications, and other sterile substances. PEF discharge is considered to be one of the premier new technologies with a great potential of replacing thermal, chemical and other pasteurization and sterilization technologies. However, there are a number of drawbacks of the PEF discharge technology. For example, ohmic heating still occurs during the PEF discharge, which causes the temperature of the liquid being treated to rise. Hence, a cooling system must be used in order to maintain the liquid at a low temperature. A significant amount of energy is wasted with unwanted heating and cooling of the liquid. Also, the requirement of a cooling system adversely increases the time required to treat the liquid. In addition, the PEF electrodes are immersed directly in the liquid. Since the electrodes contact the liquid, they are regarded as a major contamination source to the liquid due to oxidation of the electrodes during discharge. The electrodes must therefore be replaced regularly, which increases maintenance time and costs.
• With respect to ozonation, numerous research reports have demonstrated the antiviral effect of ozone exposure. For example, K. H. Wells, J. Latino, J. Gavalchin and B. J. Poiesz,Blood,78, 1882-90 (1991), reported more than 11 logs inactivation of HIV-1 virus in human blood that was exposed to ozone at a concentration of 1,200 ppm for two hours. J. M. Vaughn, Y. S. Chen, K. Lindburg and D. Morales,Appl. Environ. Microbiol.,53, 2218-21 (1987), reported the use of ozone to inactivate simian rotavirus SA-11 and human rotavirus type 2 (Wa) at 4° C. by using single-particle virus stocks, and found that although the human strain was clearly more sensitive, both virus types were rapidly inactivated by ozone concentrations of 0.25 mg/liter or greater at all pH levels tested.
• Use of ozone to kill viruses in blood and blood products has received increasing attention in the medical field, due to its high effectiveness, cost efficiency, and simplicity, with minimal collateral damage to blood cellular metabolism. Ozone is a strong oxidative, and can react with blood to form compounds which are identical to those produced by a human's own immune system to destroy viruses and bacteria. Some of these compounds include oxygen atoms, hydrogen peroxide, and lipid peroxide. Research in the Wells et al. article has indicated that the antiviral effects of ozone include viral particle disruption, reverse transcriptase inactivation, and/or a perturbation of the ability of the virus to bind to its receptor on target cells. Based on a study on the mechanism of enteroviral inactivation by ozone withpoliovirus1 as the model virus, D. Roy, P. K. Wong, R. S. Engelbrecht and E. S. Chian,Appl. Environ. Microbiol.,41, 718-23 (1981) concluded that the damage to the viral nucleic acid is the major cause ofpoliovirus1 inactivation by ozone.
• In addition, use of ozone is entering commercial practice for purification of bottled water, but requires strict limitation of its concentration because of concerns over potential formation of the suspected carcinogen bromate when excess ozone concentration is permitted to interact with minerals in the water. This becomes an even greater concern when treating biological fluids, such as blood products since ozone can dissolve in the water of the blood plasma and therefore remain for an extended period of time. With biological fluids, the ozone must therefore be “inactivated” through the passage of time or by some other method. The lingering ozone may be an advantage for purifying bottled water, but in biological fluids, control of all biochemical process is critical.
• Thus, while ozone and other minimally thermal methods are being researched for treatment of biological fluids, improved methods are desired for treating biological fluids such as blood without degrading their natural characteristics or generating toxic byproducts.
SUMMARY
• One embodiment of the present invention is directed to a method of at least partially disinfecting biological fluid of a mammal, which comprises pathogens. The method includes: (a) drawing the biological fluid from the mammal; (b) contacting a non-thermal plasma with the biological fluid to kill at least a portion of the pathogens within the biological fluid; (c) filtering toxins from at least some components of the biological fluid after contacting in step (b); and (d) returning the biological fluid to the mammal after filtering the toxins in step (c).
• Another embodiment of the present invention is directed to a method of at least partially disinfecting biological fluid of a mammal, which comprises pathogens. The method includes: (a) contacting a non-thermal plasma with the biological fluid to kill at least a portion of the pathogens within the biological fluid; and (b) filtering toxins from at least some components of the biological fluid after contacting in step (a).
• Another embodiment of the present invention is directed to a liquid-gas mixture comprising a mammalian biological liquid, gas bubbles, and a non-thermal plasma.
BRIEF DESCRIPTION OF THE DRAWINGS
• FIG. 1 is a diagrammatic view of a “silent type”, volume discharge non-thermal plasma reactor, which can be used for disinfecting biological fluids to destroy live pathogens living in the fluids.
• FIG. 2 is a diagram, which schematically illustrates a non-thermal plasma liquid disinfection system that introduces gas bubbles into the liquid being disinfected according to one embodiment of the present invention.
• FIG. 3 is a diagram illustrating a Venturi tube injector, which can be used for introducing gas bubbles within the system shown inFIG. 2.
• FIG. 4 is a diagram, which schematically illustrates a cross-sectional view of a non-thermal plasma reactor, which has a winding, serpentine flow path, according to one embodiment of the present invention.
• FIG. 5 is a cross-sectional view of a tubular non-thermal plasma reactor according to an alternative embodiment of the present invention.
• FIG. 6 is a perspective view of a non-thermal plasma reactor having narrow strip electrodes.
• FIG. 7A is a side plan view of a surface discharge-type non-thermal plasma reactor according to another alternative embodiment of the present invention.
• FIG. 7B is a plan view of a surface discharge electrode used in the reactor shown inFIG. 7A.
• FIG. 8 is a side view of a non-thermal plasma reactor in which the liquid is sprayed into the reaction volume, according to another alternative embodiment of the present invention.
• FIG. 9 illustrates a non-thermal plasma reactor having a set of barriers used to increase back pressure within the liquid being treated.
• FIG. 10 is a simplified, perspective view of two mesh-type non-thermal plasma electrodes that can be used for disinfecting liquids according to another alternative embodiment of the present invention.
• FIG. 1 is a diagram of a disinfection system having five NTP reactors connected together in series.
• FIG. 12 is a graph showing the level of inactivation ofEscherichia coliandSalmonellain cow blood samples.
• FIG. 13 is a graph illustrating red blood cell count as a function of the number of NTP stages in and NTP system and the type of injected gas (air or oxygen).
• FIG. 14 is a graph illustrating white blood cell count as a function of the number of NTP stages in the system and the type of injected gas (air or oxygen).
• FIG. 15 is a graph illustrating plasma hemoglobin in milligrams per deciliter (mg/dl) as a function of the number of NTP stages in the system and the type of injected gas (air or oxygen).
• FIG. 16 is a graph illustrating plasma APTT in seconds as a function of the number of NTP stages in the system and the type of injected gas (air or oxygen).
• FIG. 17 is a graph illustrating hematology fibrinogen in grams per deciliter (g/dl) as a function of the number of NTP stages in the system and the type of injected gas (air or oxygen).
• FIG. 18 is a block diagram illustrating an NTP system having a gas-liquid separator according to one embodiment of the present invention.
• FIG. 19 is a diagram, which schematically illustrates a multiple-plate non-thermal plasma reactor according to another embodiment of the present invention.
• FIG. 20 is a diagram that schematically illustrates a two-dielectric barrier NTP reactor having a discharge initiation region according to another alternative embodiment of the present invention.
• FIG. 21 is a diagram, which illustrates an NTP reactor according to another alternative embodiment of the present invention.
• FIG. 22 is a diagram, which schematically illustrates an NTP reactor according to another embodiment of the present invention.
• FIG. 23 is a top plan view of one of the NTP cells shown inFIGS. 19-22, according to one embodiment of the present invention.
• FIG. 24 is a cross-sectional view of the NTP cell, taken along lines24-24 ofFIG. 23.
• FIG. 25 is a cross-sectional view of the NTP cell taken along lines25-25 ofFIG. 23.
• FIG. 26 is a diagram, which schematically illustrates an NTP reactor according to another alternative embodiment of the present invention.
• FIG. 27 is a cross-sectional view of a cylindrical NTP cell according to an alternative of the present invention.
• FIG. 28 is a cross-sectional view of the NTP cell taken along lines28-28 ofFIG. 27.
• FIG. 29 is a diagram, which schematically illustrates an NTP reactor in which the NTP cell shown inFIGS. 27 and 28 can be used.
• FIG. 30 is a diagram, which illustrates a conical NTP reactor according to another alternative embodiment of the present invention.
• FIG. 31 illustrates a non-thermal plasma reactor in which the liquid is sprayed into the reaction volume, according to another alternative embodiment of the present invention.
• FIG. 32 is a diagram, which illustrates an NTP reactor that forms a liquid curtain according to another alternative embodiment of the present invention.
• FIG. 33 is a diagram illustrating an experimental test apparatus that was used for testing NTP treatments on fresh cow blood.
• FIG. 34 is a graph illustrating bacterial inactivation for each sample treated in the apparatus shown inFIG. 33 as a function of treatment time.
• FIG. 35 is a graph illustrating concentration of plasma hemoglobin in the blood samples as a function of treatment time for the apparatus shown inFIG. 33.
• FIG. 36 is a graph illustrating concentration of white blood cells (WBCs) in the blood samples as a function of treatment time.
• FIG. 37 is a graph illustrating concentration of red blood cells (RBCs) in the blood samples as a function of treatment time.
• FIG. 38 is a graph illustrating concentration of Total Plasma Protein (TPP) in the blood samples as a function of treatment time.
• FIG. 39 is a graph illustrating concentration of fibronigen in the blood samples as a function of treatment time.
• FIG. 40 is a diagram, which schematically illustrates a catheter that can be used for in-vivo NTP treatment according to one embodiment of the present invention.
• FIG. 41 is a diagram, which schematically illustrates a further catheter that can be used for in-vivo NTP treatment according to an alternative embodiment of the present invention.
• FIG. 42 is a diagram illustrating an ex-vivo circulatory system and method for disinfecting the blood of a live mammal patient using non-thermal plasma according to another embodiment of the present invention.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
• FIG. 1 is a diagrammatic view of a “silent type”, volume dischargenon-thermal plasma reactor100, which can be used for pasteurizing and/or at least partially sterilizing or disinfecting living-mammal-instillable liquids, such as biological fluids, to kill live pathogens living in the liquids.Non-thermal plasma reactor100 includes aliquid inlet102, aliquid outlet104, areaction volume106 betweenliquid inlet102 andliquid outlet104,electrodes108 and110, anddielectric barriers112 and114. Flowpath116 indicates the liquid flow path frominlet102 tooutlet104, throughreaction volume106. Each of theelectrodes108 and110 is physically and electrically isolated from the liquid inflow path112 by a respective one of thedielectric barriers112 and114.
• Dielectric barriers112 and114 are separated from one another by a gap, which defines the effective width ofreaction volume106.Dielectric barriers112 and114 can include Teflon, glass, ceramic or epoxy resin, for example. Other insulating materials can also be used. In one embodiment, eachelectrode108 and110 is embedded within an epoxy resin. The discharge gap betweenelectrodes108 and110 can be sized to suit a particular application. For example,electrodes108 and110 can be separated by a distance of up to 30 centimeters. A larger gap can be used if voltage and insulation conditions permit. In one particular embodiment,electrodes108 and110 are separated by 10 millimeters, with an effective gap betweendielectric layers112 and114 of about 7 millimeters.
• Electrodes108 and100 can have a variety of configurations. For example in the embodiment shown inFIG. 1,electrodes108 and110 are each formed of a thin, planar sheet of conductive metal, such as a copper foil. Other conductive structures can also be used such as a conductive mesh, wire or strip. The combination ofelectrodes108 and110 can have a variety of different types, such as plate-to-plate, mesh-to-mesh, plate-to-wire, wire-to-wire, plate-to-mesh and wire-to-mesh, for example. The shapes ofelectrodes108 and110 can also be varied. For example,electrodes108 and110 can be arranged coaxially with one another, wherein the outer electrode is tubular and the inner electrode is either tubular or a wire. Other arrangements can also be used. However, in each arrangement, bothelectrodes108 and110 are physically and electrically isolated from the liquid in the reaction volume by a dielectric barrier in order to prevent an electrical conduction path through the liquid and contamination of the liquid due to contact with the electrodes.
• Highvoltage power supply124 supplies power toelectrodes108 and110.Electrode108 is electrically coupled to afirst terminal120 ofpower supply124, andelectrode110 is electrically coupled to asecond terminal122 ofpower supply124. One of theelectrodes108 and110 serves a ground electrode, such aselectrode110, and the other, such aselectrode108, serves as a high voltage electrode.Power supply124 can include a continuous direct-current (DC) or an alternating-current (AC) power supply that is capable of producing a voltage acrosselectrodes108 and110 so as to form an electric discharge path, shown byarrows126, acrossreaction volume106. In one embodiment, the voltage potential generated betweenelectrodes108 and110 is in the range of 1 kV-35 kV, for example. Other voltage ranges can also be used, such as voltage ranges between 1 kV and 500kV. Power supply124 can be operated at either low or high frequencies and can produce pulses with a single polarity or can produce bipolar pulses.
• Withelectrodes108 and110 having opposite polarity,electrodes108 and110 generate a strong electrical field acrossreaction volume106. The strong electrical field is applied to gas in the liquid, which generates non-thermal plasma species, including electrically neutral gas molecules, charged particles in the form of positive ions, negative ions, free radicals and electrons, and quanta of electromagnetic radiation (photons). Examples of the generation of these highly reactive species include, but are not limited to:
• e+O₂----->O₂⁺+2e
• • O⁺+O+2e
  • O*+O+e
  • O⁻+O
• e+N₂----->N₂⁺+2e
• • N⁺+N+2e
  • N₂*+e
  • N*+N+e
• O*+H₂O----->2OH
• O+O₂+O₂----->O₃+O₂
• e+H₂O----->H+OH
• These non-thermal plasma species are highly reactive and are effective in destroying live pathogens, such as bacteria, viruses and fingi, living in the liquid being treated. The non-thermal plasma species are extremely strong oxidants that break down chemicals and kill microorganisms instantly. A non-thermal plasma is one in which the mean electron energy is much higher than that of the bulk-gas (or liquid) molecules. Energy is added to the electrons instead of the ions and bulk gas (or liquid) molecules. The electrons can therefore attain high energies, while the background molecules and ions remain at ambient temperature. Because of the non-thermal nature ofreactor100,reactor100 preserves the quality and other heat-sensitive attributes of the liquids being disinfected.
• Examples of liquids that can be treated include any liquid that is produced by or secreted by a living mammal, such as blood, tissue fluid, cerebrospinal fluid, or lymph; or a liquid that is biocompatible with the physiology of, and therefore beneficially instillable in a living mammal, such as a human, dog, horse, cat, etc. The term “instillable” includes all liquids that are non-toxic to a living mammal when introduced into the mammal by methods such as oral ingestion, inhaling, transdermal absorption, rectal (as with enema or other such solutions), direct insertion into arterial vessels, venal vessels (IV), lymphatic vessels, the spinal canal, and body cavities such as the abdomen, the lungs or the liver, intramuscular injection, and subcutaneous injection.
• One example of such a liquid is a liquid that is capable of being consumed and assimilated by a living mammal as nourishment. Other treatable liquids may include fermentation broth, medications and vaccines of all types, total parenteral nutrition (TPN) liquids, including sugars and lipids, etc., intravenous (IV) fluids such as Lactated Ringers or D5, etc., renal dialyzing fluids (which are instilled and drawn back off), and biological fluids that must be returned to the body without damage to viable components such as platelets and leukocytes. These biological fluids can include heat-sensitive fluids such as human and animal bloods, blood products, such as plasma or lymph, extracellular tissue fluid, and cerebrospinal fluid (CSF).
• Of these biologic fluids, the most important is blood, which brings the vital oxygen and nourishment to the organs of the body. When a mammal is infected with either a bacterial or viral pathogen, the blood is the carrier. Bacteria feed on the blood elements and reproduce uncontrollably; virus enters the blood cells and reproduces, but free virus is also carried throughout the body to contaminate other types of cells. The mammal's immune system combats and destroys the pathogens, but serious infections can overwhelm the body's immune system and compromise the innate ability to recover.
• Blood is made up of plasma, the saline-and-water-based liquid that dissolves electrolytes such as sodium, calcium, and potassium, lipids, and vitamins, and carries the red blood cells (RBC, or erythrocytes), white blood cells (WBC, or leukocytes), and platelets (clot-supporting cells). Other minor fractions include hormones, antibodies, and albumin. But, when an infection occurs, the critical issue is cleansing the plasma, preventing it from carrying the infectious agents throughout the body, and choking off the major blood cell functions. Generally, lipids, electrolytes, vitamins, and other nutrients can be added intravenously as long as there is a minimal level of viable blood plasma and healthy cells to carry out basic functions. When blood volume is low, frequently fresh frozen plasma is added to increase blood volume.
• Electrically-generated non-thermal plasma species can be used to inactivate pathogenic and spoilage microorganisms under “ambient” conditions, such as ambient temperature and atmospheric pressure or in non-ambient conditions. In one embodiment, “ambient” refers to the body's environment of approximately 37 degrees C. Non-thermal plasma is not the same substance as blood plasma. The term “non-thermal plasma” used in the specification and claims refers to a state of matter, such as a gas, atmosphere or liquid to which a specific amount of energy has been added to separate the component molecules into a collection of ions, electrons, free radicals, charge-neutral molecules, and other species in varying degrees of excitation. The term “blood plasma” refers to a saline and water carrier of the various blood fractions.
• The non-thermal plasma used in this embodiment is a true non-thermal process, which disinfects or sterilizes biological fluids at the temperature of the host organism, but does not appear to pose a threat to the desirable properties of the fluids. For example, a five-log reduction in bacteria such asEscherichia coliand Salmonellae inoculated in biological fluids such as blood can be achieved with non-thermal plasma. As described in more detail below, hematology and morphology studies have shown that non-thermal plasma treatment does not cause significant changes in blood properties. The values for blood cell count, plasma hemoglobin, coagulation profile, and morphology of the treated blood samples were within the normal ranges following treatment.
• In one embodiment of the present invention, it has been found that the reduction in pathogens living in the liquid being treated can be greatly enhanced if fine gas bubbles are introduced into the liquid being treated by the non-thermal plasma. The interaction of gas bubbles with the non-thermal plasma has been found to enhance the disinfection effectiveness by significantly enhancing the exposure of the host fluid to the highly reactive NTP species. The resulting liquid-gas mixture can include a gas dispersed in a liquid or a liquid dispersed in a gas. The gas can be mixed with the liquid in a variety of ways, such as by diffusion or injection. Various gas injection devices can be used, such as a Venturi tube gas injector made by Mazzei Injector Corporation. Alternatively, the liquid can be sprayed through the reaction chamber to form droplets of liquid separated by gas. In one embodiment, the liquid-gas mixture has a thickness alongflow path116 of 0.1 millimeters to 30 millimeters, for example. Other thicknesses can also be used.Reactor100 can be constructed in various arrangements to expose the liquid-gas mixture to the plasma discharge for any treatment time, such as between 0.1 second to 10 minutes, for example. Other treatment times can also be used.
• Introducing fine gas bubbles into the liquid greatly enhances the generation of plasma inreactor100 for killing pathogens living in the liquid being treated. As the gas-liquid mixture is passed throughNTP reactor100, the gas bubbles in the liquid become excited by the applied electric field, generating non-thermal plasma. The non-thermal plasma species then interact with and kill pathogens living in the liquid. Parameters associated with gas injection include composition of the gas, amount and distribution of the gas in the liquid, the size of the gas bubbles, velocity of the liquid relative to the physical motion of the gas, and the gas injector orifice size. Experiments have shown in liquid containing gas bubbles, especially with a gas containing 90% oxygen, bacteria kill is increased substantially as compared to the bacteria kill in liquid containing no gas bubbles.
• Various factors that may affect the killing power of the reactive NTP species withinreaction volume106 include the ratio of gas to liquid (from very low to very high), size of gas bubbles, degree of mixing of gas and liquid, and compositions of the gas and liquid. Preferably, the system is adapted to obtain at least a one log, and more preferably at least a 5 log to 10 log reduction in pathogens living in the liquid. This is a highly controllable and scalable process. In general, the liquid flow rates as described in this embodiment are sufficient to permit the liquid to pass through consecutive NTP chambers, with a pathogen reduction of approximately one log per chamber, for example. Thus, liquid can cycle three, or five, or ten times, and the pathogen-inactivation effect is essentially proportional. A high gas-to-liquid ratio can be obtained by injecting the liquid into a gas phase. For example, it was observed that the killing power of the NTP species was greater with smaller gas bubbles than with larger gas bubbles. Also, it has been found that the more evenly the gas bubbles are distributed in the liquid, the more effective the non-thermal plasma generation and pathogen reduction. In one embodiment, the ratio of gas volume to liquid volume (Gas Volume/Liquid Volume) is preferably 0.1 to 20, more preferably 0.3 to 5, and most preferably 0.5 to 1. However, other ratios outside these ranges can also be used. A variety of gas compositions can be used, such as air, oxygen, ozone and nitrogen, or a mixture of these or other gases. One type of gas may be more effective than another in a particular application, depending on the type of liquid and the types of pathogens being killed. For example, the gas bubbles can consist of 100% by volume oxygen (e.g., O₂) or 100% by volume nitrogen.
• FIG. 2 is a diagram, which schematically illustrates a non-thermal plasmaliquid pasteurization system200 that introduces gas bubbles into the liquid according to one embodiment of the present invention.System200 includesliquid source tank202, pump204,gas mixing device206,non-thermal plasma reactor208, highvoltage power supply210 andliquid receiving tank212.Source tank202, pump204,gas mixing device206,non-thermal plasma reactor208 and receivingtank212 are coupled in series with one another within atreatment flow path214, which can be formed of a series of tubes or other liquid channels for passing the liquid to be treated from one element inpath214 to the next.
• Tank202 contains the liquid to be treated. Pump204 pumps liquid fromtank202 totank212, throughtreatment flow path214. Additional pumps can be placed at various locations alongtreatment flow path214 in alternative embodiments. Also, pump204 can be eliminated in embodiments in which another mechanism, such as gravity, is used for moving the liquid alongtreatment flow path214. The output ofpump204 is coupled to the input ofgas mixing device206. The flow rate of the pump is set based on factors such as the desired treatment time, the applied voltage, the dimensions/structures ofreactor208, and the size ofgas mixing device206.Gas mixing device206 can include any device that is capable of introducing gas bubbles into the liquid flowing throughtreatment flow path214. Various mixing devices can be used, such as a gas diffuser or a gas injector. In one embodiment,gas mixing device206 includes a Venturi tube injector. Other types of gas mixers can also be used.Gas mixing device206 has agas inlet216 for receiving the gas to be mixed into the liquid.
• The gas-liquid mixture is then provided toliquid inlet220 ofnon-thermal plasma reactor208.Reactor208 can includereactor100 shown inFIG. 1, for example. Highvoltage power supply210 is electrically coupled to the electrodes withinreactor208. As the gas-liquid mixture passes throughreactor208, fromliquid inlet220 toliquid outlet222, the non-thermal plasma generated inreactor208 disinfects the liquid by destroying at least a portion of the live pathogens such as bacteria or viruses living in the liquid. The treated liquid then exits throughliquid outlet222 and is collected in receivingtank212.
• In one embodiment, the liquid being treated withinreactor208 is kept under a pressure that is greater than an ambient pressure surrounding the reactor so as to maintain the gas bubbles substantially uniformly distributed in the liquid and of a small size. The pressure can be increased by providingliquid outlet222 with a cross-sectional area that is less than the cross-sectional area ofliquid inlet222. Also, the internal reactor flow path can be designed to provide a back pressure in the liquid and to provide turbulent flow.
• FIG. 3 is a diagram illustrating aVenturi tube injector300, which can be used for thegas mixing device204 shown inFIG. 2.Injector300 has amain flow path302 between aninlet304 and anoutlet306 and has aflow constriction308. Agas inlet310 is coupled to themain flow path302 at theflow constriction308. As liquid flows along main flow path302 a pressure difference betweeninlet304 andoutlet306 creates a vacuum inside the injector body, which draws gas into the injector throughgas inlet310 and results in a mixture of gas and liquid atoutlet306. A Venturi tube injector is a high efficiency, differential pressure injector. It has been found that this type of injector mixes gases with liquids very well. As a result, bubbles in the gas-liquid mixture produced at the output ofinjector300 are extremely fine and uniformly distributed.
• FIG. 4 is a diagram, which schematically illustrates a cross-sectional view of a non-thermal plasma reactor which has a winding, serpentine flow path and can be used for reactor208 (shown inFIG. 2) according to one embodiment of the present invention.Reactor400 includes a liquid-gas inlet401, a treated liquid-gas outlet402 and a plurality of oppositely polarizednon-thermal plasma electrodes404 and406 which are arranged to form a serpentine liquid flow path indicated byarrows408. As described above, eachelectrode404 and406 is physically and electrically isolated from the liquid flow path by a respective dielectric barrier. In one embodiment,electrodes404 and406 are each formed as a planar electrode panel that is parallel to and separated from the other electrode panels. Eachelectrode panel404 and406 has a polarity that is opposite to the polarity of the next adjacent electrode panel. This creates a plurality of reaction volumes, which are coupled together in series to formflow path408. Each reaction volume is defined by the gap between a respective pair ofelectrodes404 and406. The serpentine flow path can be used to increase the liquid residence time withinreactor400 and to increase the turbulence of the liquid flow, which may assist in keeping the gas bubbles more evenly distributed and of a small size in the liquid. Any number of reaction volumes can be used in alternative embodiments. For example,reactor400 can include a single reaction volume such as shown inFIG. 1, two reaction volumes that form a U-shaped flow path, or a plurality of reaction volumes as shown inFIG. 4. In an alternative embodiment, the individual reaction volumes extend parallel to one another frominlet401 tooutlet402.
• FIG. 5 is a cross-sectional view of a tubularnon-thermal plasma reactor500 according to an alternative embodiment of the present invention.Reactor500 has a tubular structure, with flow going into or out of the page inFIG. 5.Reactor500 includes atubular ground electrode502 and a wirehigh voltage electrode504, which is coaxial withelectrode502. In an alternative embodiment,electrode502 is a high voltage electrode andelectrode504 is a ground electrode.Electrodes502 and504 are separated by a gap, which defines areaction volume506.Electrodes502 and504 are physically and electrically isolated fromreaction volume506 by respectivedielectric barriers508 and510.Dielectric barriers508 and510 preventelectrodes502 and504 from contaminating the liquid being treated and provide electrical isolation that prevents the liquid withinreaction volume506 from shortingelectrode502 toelectrode504.
• FIG. 6 is a perspective, schematic view of anon-thermal plasma reactor600 havingnarrow strip electrodes602 and604.Electrodes602 are biased at one polarity, andelectrodes604 are biased at an opposite polarity. Electrode strips602 and604 are arranged perpendicular to one another and are spaced about a reaction volume. Eachindividual electrode602 and604 is insulated by a dielectric barrier. For example, all of theelectrodes602 can be embedded within one sheet of dielectric material, and all of theelectrodes604 can be embedded within another sheet of dielectric material. With this type of electrode structure, the local electric fields aroundelectrodes602 and604 are greatly enhanced, which ensures discharge takes place easily and effectively in the gas bubbles.
• FIG. 7A is a side cross-sectional view of anon-thermal plasma reactor700 according to another alternative embodiment of the present invention.Reactor700 includes ahousing702 and at least one “surface”discharge electrode704.Housing702 has aliquid inlet706, aliquid outlet708 and a pair offlow paths710 extending on either side ofsurface discharge electrode704.Surface discharge electrode704 includes a plurality ofadjacent conductors712 and714 having opposite polarity.Conductors712 and714 are electrically insulated fromflow paths710 by adielectric material715. In one embodiment,conductors712 and714 are each individually coated with a dielectric material that forms an electrically insulating sheath. In an alternative embodiment,conductors712 and714 are embedded in a dielectric material to form an electrode sheet.Conductors712 and714 can have diameters of about 0.1 to about 3.0 millimeters, for example, and are each separated by a gap in the range of 0 to 6 millimeters, for example.
• Excitation ofconductors712 and714 generates micro-current electricfield discharge paths716 along the surfaces ofelectrode704. Electric field discharge throughdischarge paths716 generates non-thermal surface plasma species within the liquid being treated, along the surface ofelectrode704. These non-thermal surface plasma species are highly reactive and destroy pathogens living in the liquid, similar to the embodiments discussed above.Electrode704 can have a variety of shapes, such as planar or tubular.FIG. 7B is a plan view ofelectrode704 in planar form, which illustrates one possible arrangement ofconductors712 and714.
• FIG. 8 is a side view of anon-thermal plasma reactor800 according to another alternative embodiment of the present invention.Reactor800 includesfluid inlet801,fluid outlet802,electrodes804 and806 anddielectric barriers808 and810.Electrodes804 and806 are separated from one another by a gap, which defines a reaction volume betweendielectric barriers808 and810.Reactor800 further includes asprayer812, which is coupled tofluid inlet801 for receiving the liquid to be treated.Sprayer812 spays the liquid through the reaction volume, betweendielectric barriers808 and810 to form a fine mist within the reaction volume. The treated liquid then exits throughliquid outlet802.Sprayer812 assists in generating a gas-liquid mixture within the reaction volume, which helps the non-thermal plasma in destroying pathogens living in the liquid.
• FIG. 9 illustrates anNTP reactor900 having a set of barriers used to increase the back pressure within the liquid being treated. Briefly referring back toFIG. 2, the stream of the gas-liquid mixture fromgas mixing device206 toreactor208 is of high speed and high pressure. To some extent, the distribution of gas bubbles in the liquid depends on the back pressure of the mixture. The higher the back pressure, the higher the solubility of the gas in the liquid. In one embodiment, alarge tank202 can be used to increase the back pressure in the system.
• In the embodiment shown inFIG. 9, the arrangement of electrode panels is used to increase the back pressure. As liquid is pumped throughtube901,gas injector902 draws gas intogas inlet903 and produces a gas-liquid mixture at the outlet of the injector.Tube904 delivers the gas-liquid mixture fromgas injector902 toinlet908 ofNTP reactor900.NTP reactor900 has a plurality ofelectrode plates905 and906, which are arranged to form a serpentine flow path frominlet908 tooutlet909 and are arranged perpendicular toinlet908. With this arrangement,electrode plates905 and906 form barriers to the liquid stream entering frominlet908 and being passed from one portion of the flow path to the next. These barriers further increase back pressure within the gas-liquid mixture.
• FIG. 10 is a simplified, perspective view of two mesh-typenon-thermal plasma electrodes920 and922 that can be used for pasteurizing liquids according to another alternative embodiment of the present invention.Electrodes920 and922 are each formed of a conductive wire mesh, which has been coated with a dielectric material such that the wire mesh is electrically insulated from the liquid being treated. The dielectric coating is formed so that the area between each conductive segment in the mesh is open to fluid flow. Any coating technique can be used, such as physical vapor deposition (PVD) or chemical vapor deposition (CVD).
• The liquid to be treated is passed throughelectrodes920 and922 in the direction ofarrow924, substantially perpendicular to the planes formed byelectrodes920 and922. As the liquid passes throughmeshes920 and922,electrodes920 and922 are electrically coupled to opposite voltage potentials, which creates a non-thermal plasma withingap926 for treating the liquid present within the gap. If the openings inelectrodes920 and922 are sufficiently small, the openings can further assist in breaking-up larger gas bubbles and maintaining the gas bubbles in the liquid at a sufficiently small size. Other arrangements can also be used, and meshes920 and922 can be non-planar. Also, a series of electrode pairs920 and922 can be used, wherein the liquid flows sequentially through each electrode pair for treatment. In an alternative embodiment, a gas injector or diffuser is not used to mix the gas and liquid. Rather, the gas is supplied through a tube into the reactor and is then broken into small bubbles as the gas and liquid are forced through the small openings in the mesh electrodes.
1. Experimental Results
• Several experiments were performed to demonstrate the effectiveness of non-thermal plasma in reducing pathogens living in a biological fluid.
• For example, the NTP pasteurization system shown inFIG. 11 was built and used to treat fresh cow blood samples.System1000 included fiveNTP reactors1001 connected together in series with eachNTP reactor1001 having itsown source tank1002,pump1003 andgas injector1004. The outlet of eachNTP reactor1001 was coupled to thesource tank1002 of thenext reactor1001 in the series. The plurality ofgas injectors1004 ensured that the gas-liquid mixture contained sufficiently fine bubbles throughout the flow. Air was injected through eachinjector1004 at 2 cubic feet per hour (CFH).Pumps1003 pumped the liquid throughsystem1000 at 30 gallons per hour. The electrical connections to theNTP reactors1001 were coupled together in parallel with one another and were excited at 20-30 kV alternating-current (AC) voltage.
• Eachreactor1001 had a similar structure as that described with reference toFIG. 4, but with only two individual reaction volumes coupled in series with one another to form a serpentine flow path. Each electrode panel was formed of a thin, flat solid copper plate, which was attached to the backside of an epoxy resin board such that the copper plate was physically isolated from the liquid being treated. The epoxy resin board served as a dielectric layer, which had a thickness of 1.5 millimeters. The discharge gap between the dielectric layers, across the reaction volume, was 7 millimeters. The effective discharge volume for each leg of the serpentine flow path was 500 millimeters by 10 millimeters by 7 millimeters. These parameters were used as examples only and can be further modified or optimized for treating a particular biological fluid in a particular manner with one or more NTP reactors for a particular gas, such as oxygen.
• Each test was conducted with a one liter cow blood sample that was inoculated with more than five logs of eitherEscherichia coliorSalmonella. The tests were conducted under three conditions: (1) without gas injection; (2) with air injection; and (3) with oxygen injection. The output from each stage was sampled atsource tanks1002 to verify the reduction of bacteria at different stages of the system.
• a. Inactivation ofEscherichia coliandSalmonella
• FIG. 12 shows the level of inactivation ofEscherichia coliandSalmonellain the blood samples. The test results inFIG. 12 show that NTP treatment can cause five logs ofEscherichia coliandSalmonellareduction under the condition outlined above. No difference in bacterial inactivation was found betweenEscherichia coliandSalmonella. Oxygen as a mixture gas media in biological fluids was more effective than air. One possible explanation is that air has more nitrogen, which requires higher ionization energy than oxygen, and therefore the concentration of energetic radicals in non-thermal plasma would be lower in air than in oxygen.
• b. Change in Hematological Properties of Blood Samples
• Blood is regarded as one of the most delicate biological fluids. Hematology and morphology studies were also performed on the samples to verify that non-thermal plasma treatment does not cause significant changes in the biologically active ingredients in blood. These studies included tests on blood specifications of hematology, such as morphology, blood cell count, blood plasma hemoglobin, and coagulation profile, the results of which are shown inFIGS. 13-17. The morphology of blood cells remained normal after treatment.
• FIG. 13 is a graph illustrating the red blood cell count as a function of the number of NTP stages in the system and the type of injected gas (air or oxygen).FIG. 14 is a graph illustrating the white blood cell count as a function of the number of NTP stages in the system and the type of injected gas (air or oxygen). FromFIGS. 13 and 14, it is seen that red blood cell count and white blood cell count did not change significantly. The small variations noticed in the test results may be caused by statistical error and the non-uniform distribution of blood cells.
• FIG. 15 is a graph illustrating blood plasma hemoglobin in milligrams per deciliter (mg/dl) as a function of the number of NTP stages in the system and the type of injected gas (air or oxygen). The blood plasma hemoglobin increased after treatment. Although the hemoglobin increased after treatment, the blood plasma activated partial thromboplastin time (APTT) and fibrinogen showed no significant difference before and after treatment as shown inFIGS. 16 and 17.
• FIG. 16 is a graph illustrating blood plasma APTT in seconds as a function of the number of NTP stages in the system and the type of injected gas (air or oxygen). Normal APTT for a cow is 6.8 to 9.2 seconds. The test on blood plasma APTT varied from 7.5-8.6 after NTP treatment. They are within the normal range of 6.8 to 9.2 seconds for ATPP in a cow.
• FIG. 17 is a graph illustrating hematology fibrinogen in grams per deciliter (g/dl) as a function of the number of NTP stages in the system and the type of injected gas (air or oxygen). The hematology fibrinogen values varied from 0.1-0.35 g/dl as a result of NTP treatment, which are also within a normal range of 0.1-0.7 g/dl for cow blood.
• The conclusions from the above-experiments are that a five-log reduction of bacteria (Escherichia coliand Salmonellae) inoculated in cow blood can be achieved using the NTP system ofFIG. 11, and the NTP treatments do not cause significant changes in blood hematology and morphology. Red and white blood cell counts do not change significantly. While the blood plasma hemoglobin increases after treatment, the values of blood plasma fibrinogen and APTT remain within normal ranges after treatment.
2. Coagulation of Blood and Self-Cleaning of NTP System
• Coagulation of biological fluids is a normal phenomenon. After a specified period of use or after a particular treatment or set of treatments, the NTP system should be cleaned to deodorize the NTP system and to prevent different types of biological fluid samples treated by the same system from contaminating each other (i.e., cross contamination). The NTP system shown inFIG. 11 and the systems of various other embodiments of the present invention lend themselves well to cleaning. The system can be flushed with sterile water to prevent a biological film from forming on the contacting surfaces of the system. During the water cleaning/flushing process, NTP system can be electrically operated to produce ozone and ozonated water within the system which aid in cleaning the reactors, pipes, pumps, etc. in the system. The ozone-aided self-cleaning process has been found to be very effective in cleaning and deodorizing the NTP system and in preventing cross contamination. The entire process of cleaning such blood-circulating apparatus is well-known in the art, having been practiced for many years for hemodialysis. The present invention utilizes the same principles and methods of between-use disinfection.
• Also, the contacting surfaces of the system, such as the electrode surfaces, can be covered with a thin film coating to reduce biological fluid coagulation and biological film formation. Any biologically-safe low-friction coating can be used, such as polytetrafluoroethylene (PTFE) which is available under the tradename TEFLON from E.I. du Pont de Nemours and Company.
3. Separation of Gas From Blood or Other Biological Fluids
• As discussed above, gas injection into the biological fluids being treated is helpful in inducing non-thermal plasma species that react with the pathogenic microorganisms within the fluids. It was shown that the injected gas, especially oxygen, is a helpful agent in promoting bacterial inactivation (SeeFIG. 12). Following NTP treatment it is often desirable for the injected gas to be separated from the treated biological fluid. The gas can be separated with a gas separator.
• FIG. 18 is a block diagram illustrating anNTP system2000 having a gas separator according to one embodiment of the present invention.NTP system2000 includes a rawsample receiving tank2002, apump2004, agas injector2006, agas source pump2008, anNTP reactor2010, a power supply andtemperature monitor2012, gas-liquid separator2014, and pasteurizedsample tank2016. In one embodiment,gas source pump2008 can include an oxygen generator, for example.Gas separator2014 can include any suitable liquid/gas separator, and can include a vacuum source if desired for assisting in the removal of gas from the liquid. These small separators are quite common, particularly in the fuel cell industry, where it is necessary to remove carbon dioxide from the electrolyte fluids, or in bioreactors for fermentation. They operate in a variety of ways, depending on the reliability level required: gravity (gas bubbles consolidate and rise to the top), centrifuge, and pressurized types (where a reduction in fluid pressure causes gas bubbles to rise rapidly). A common design is the VIG porous Teflon™ membrane separator for the environmental treatment industry, which uses a filter that will pass only gas through it, leaving the liquid behind. Yokota manufactures a “de-foaming pump” that utilizes a combination of centrifugal and pressure forces to continuously remove high volumes of bubbles from liquid.
4. Alternative Reactor Embodiments
• FIG. 19 is a diagram, which schematically illustrates a multiple-platenon-thermal plasma reactor1500 according to another embodiment of the present invention.Reactor1500 has aliquid source tank1502 and aliquid outlet tank1504.Pump1506 draws liquid1508 fromtank1502 throughtube1510 and supplies the liquid togas injector1512 throughtube1514. As liquid1508 is pumped throughgas injector1512,gas injector1512 draws gas intogas inlet1513 and produces a gas-liquid mixture at the outlet of the injector.Tube1516 delivers the gas-liquid mixture tovalves1518, which control flow to a plurality of parallelNTP reactor cells1520. The term “tube” as used in the specification and claims can include any conduit or passage formed of any suitable material and having any suitable cross-sectional shape.
• Eachcell1520 has areaction volume1522 and a par of oppositelypolarized electrodes1524, which are electrically and physically isolated from the reaction volume bydielectric barriers1526.Tubes1528 deliver the gas-liquid mixture toreaction volumes1522 for treatment. Dashedlines1530 represent the upper surfaces of the gas-liquid mixtures in each reaction volume.Spacers1527 define the height ofreaction volumes1522, between opposing surfaces ofdielectric barriers1526.
• Highvoltage power supply1540 delivers electrical excitation energy toelectrodes1524 throughconductors1541 for generating non-thermal plasma withinreaction volumes1522. In one embodiment,power supply1540 delivers an AC voltage of 5 kV to 30 kV at a frequency of 1 Hz to 1000 Hz, for example. Other voltages and frequencies can also be used. The treated gas-liquid mixture1530 is then returned totank1504 throughtubes1542.Electrodes1524 anddielectric barriers1526 can have any structure and gap size, such as those disclosed in the present application. Any number of parallelNTP reactor cells1520 can be used in alternative embodiments of the present invention.
• FIG. 20 is a diagram that schematically illustrates a two-dielectricbarrier NTP reactor1600 having a discharge initiation region according to another alternative embodiment of the present invention. The same reference numerals are used inFIG. 20 as were used inFIG. 19 for the same or similar elements. In this embodiment, a film orplate1602 dividesreaction volume1522 into atreatment region1604 and adischarge initiation region1606.Film1602 is suspended in the space betweendielectric plates1526 byspacers1608, for example.Tube1516 delivers the gas-liquid mixture1530 intotreatment region1604, andtube1542 returns the treated gas-liquid mixture totank1504.Film1602 contains gas-liquid mixture1530 intreatment region1604 and prevents the gas-liquid mixture from entering intodischarge initiation region1606.Discharge initiation region1606 can be filled with various gases, such as air, another gas or a gas mixture.Discharge initiation region1606 can also be substantially void of any gas and held under a vacuum at below-normal atmospheric pressure. In this embodiment,electrodes1524 are parallel plates, and dischargeinitiation region1606 andtreatment region1604 are rectangular volumes.
• In one embodiment,film1602 is formed of a dielectric material, such as a transparent membrane of polytetrafluoroethylene from E.I. du Pont de Nemours and Company. In alternative embodiments,film1602 can be formed of a transparent epoxy resin or other types of film or sheet materials.Film1602 has good dielectric properties and allows one or more of the non-thermal plasma species to pass fromdischarge initiation region1606 totreatment region1604. However,film1602 should not allow the gas-liquid mixture1530 to pass intodischarge initiation region1606.Film1602 can also be non-dielectric, as long as there is at least one other dielectric barrier betweenelectrodes1524.Film1602 can also include an ion-selective membrane. In one embodiment,film1602 is made as thin as possible and transparent so as to limit absorption or reflection of the non-thermal plasma species passing through totreatment region1604. For example,film1602 can have a thickness between 0.02 millimeters to 1 millimeter. Smaller or larger thicknesses can also be used. The surfaces offilm1602 can be hydrophilic or hydrophobic. Examples of commercially available films that are effective include CS Hyde 56-10—a Teflon coated fabric that is 10 mils thick and is tan in color, TetraTex Pourous PTFE—a PTFE membrane that is white in color, and a Spetrum Lab filter disk—a 70 mm diameter Teflon mesh filter media that is semi-translucent. Other films can also be used.
• During operation,electrodes1524 are energized. The resulting electrical field between the electrodes generates non-thermal plasma species withinregions1604 and1606. Non-thermal plasma species withinregion1606 are easily generated, and the discharge acrossregion1606 is fairly uniform. This assists in generating more consistent and uniform non-thermal plasma species withintreatment region1604. Withoutdischarge initiation region1606, it has been found that the discharge within the gas-liquid mixture1530 can be inconsistent or non-uniform, depending on the particular apparatus. The NTP species generated withininitiation region1606 that pass intotreatment region1604 react with the gas-liquid mixture to kill more evenly and consistently pathogens living in the liquid.Film1602 also protects theupper electrode1524 and theupper dielectric barrier1526 from contamination or staining by gas-liquid mixture1530.
• In addition, thedischarge initiation region1606 can be used to limit the generation of ozone more easily in applications where ozone is not desired. This region can be filled with a gas other than air, such as nitrogen, carbon dioxide or another gas, and still provide an effective treatment of any live pathogens in the liquid. In these embodiments,gas injector1512 can be used to inject a gas other than air to further limit the generation of ozone. However, air can also be used if desired.Discharge initiation region1606 can also be held under a small vacuum to further limit the amount of gas in the region and therefore the amount of ozone that is generated.
• In an alternative embodiment,NTP reactor1600 further includes agas source1620, which supplies gas to dischargeinitiation region1606 through tube1622. In addition, atube1624 can by coupled betweendischarge initiation region1606 andgas inlet1513 ofgas injector1512. During operation,gas injector1512 draws gas containing the non-thermal plasma species frominitiation region1606 intogas inlet1513 to further enhance the mixture of non-thermal plasma species in the liquid being treated.Gas source1620 replaces the gas drawn out ofdischarge initiation region1606. In another embodiment the NTP species generated inregion1606 is mixed with the gas-liquid mixture1530 at the outlet ofNTP cell1520. Mixing can be accomplished through a gas injector similar toinjector1512, a diffuser or any other apparatus or method that forces or assists in the NTP species passing through or contacting the treated liquid.
• In a further embodiment (not shown inFIG. 20), asecond dielectric film1602 is positioned on the other side oftreatment region1604, betweentreatment region1604 andbottom dielectric barrier1526. The second dielectric film can be spaced from thebottom dielectric barrier1526 by a furtherdischarge initiation region1606, such that both sides oftreatment regions1604 have adischarge initiation region1606.
• One or more of thedielectric barriers1526 and1602 can be eliminated as long as there is at least one dielectric barrier betweenelectrodes1524. For example, bothdielectric barriers1526 can be eliminated such thatdielectric film1602 serves to separateregions1604 and1606 and as the sole dielectric material betweenelectrodes1524. In yet a further embodiment,dielectric film1602 is eliminated and one or both of thedielectric barriers1526 are spaced from theirrespective electrodes1524. In this embodiment, the liquid being treated will still have no direct contact withelectrodes1530, and the spaces betweendielectric barriers1526 and theirrespective electrodes1524 can be used as discharge initiation regions similar toregion1606. Also, the gas injector can be eliminated in alternative embodiments ofreactor1600 and in alternative embodiments of the reactors shown in the various other figures or discussed herein.
• FIG. 21 is a diagram, which illustrates anNTP reactor1700 according to another alternative embodiment of the present invention. Again, the same reference numerals that are used inFIG. 21 as were used inFIGS. 19-20 for the same or similar elements. In thisembodiment NTP cell1520 has adielectric film1602, which separates gas-liquid mixture1530 fromdischarge initiation region1606 and abare metal electrode1702. The upper dielectric barrier1526 (shown inFIG. 20) adjacent theupper electrode1524 has been removed. In another embodiment, thelower dielectric barrier1526 can also be removed such thatdielectric film1602 serves as the main dielectric barrier betweenelectrodes1524.
• FIG. 22 is a diagram, which schematically illustrates anNTP reactor1800 according to another embodiment of the present invention.NTP reactor1800 is similar toNTP reactor1600 shown inFIG. 20, but has nodielectric film1602.Reaction volume1522 has aheight1802 that exceeds theheight1804 of the gas-liquid mixture1530 flowing throughreaction volume1522 to create agap1806 between the upper surface ofmixture1530 and the bottom surface of theupper dielectric barrier1526. As long as thegap1806 is maintained during operation, the gap can serve as a discharge initiation region. The gap can be maintained by controlling or otherwise setting the volume flow of gas-liquid mixture1530 through the inlet and outlet ofreaction volume1522 such that the gas-liquid mixture remains confined to the treatment region.Gap1806 can be filled with air or any other suitable gas.
• FIGS. 23-25 show the electrode structure of one of theNTP cells1520 shown inFIGS. 19-22, according to one embodiment of the present invention.FIG. 23 is a top plan view of theNTP cell1520 in whichupper electrode1524 andupper dielectric barrier1526 are partially cut-away to expose a portion ofbottom dielectric barrier1526.FIG. 24 is a cross-sectional view ofNTP cell1520, taken along lines24-24 ofFIG. 23.FIG. 25 is a cross-sectional view ofNTP cell1520 taken along lines25-25 ofFIG. 23.
• InFIGS. 23-25,dielectric film1602 is removed for clarity. A pair of opposingend spacers1608 and1609 and opposingsidewall spacers1906 define the reaction volume between the upper and lowerdielectric barriers1526 and contain the gas-liquid mixture being treated.End spacer1608 has a plurality of passages1902 (shown in dashed lines inFIG. 23) for passing the gas-liquid mixture from tube1516 (shown inFIGS. 19-22) to the reaction volume. End spacer1609 (FIG. 17) hassimilar passages1902 for passing the treated gas-liquid mixture to tubes1542 (shown inFIGS. 19-22).
• Withinreaction volume1522, upper surface of thelower dielectric barrier1526 can include a plurality of raised ridges or separatingwalls1910 that maintain a dispersed flow of the gas-liquid mixture throughreaction volume1522. Separatingwalls1910 define a plurality of recessedchannels1912 along which the gas-liquid mixture flows. Separatingwalls1910 can have heights that are equal to the height ofreaction volume1522 or less than the height ofreaction volume1522.Spacers1608,1904, and1906 and separatingwalls1910 can be formed of the same material asdielectric barrier1526 or from different material.
• FIG. 26 is a diagram, which schematically illustrates anNTP reactor2200 according to another alternative embodiment of the present invention. Again, the same reference numerals are used inFIG. 26 as were used inFIGS. 19-25 for the same or similar elements.NTP reactor2200 has acylindrical NTP cell2202 having acentral axis2204, which is oriented normally (i.e., vertically) with respect to the floor on whichreactor2200 is supported and therefore parallel to the gravitational forces of the earth.NTP cell2202 has alower end2216, anupper end2218, a cylindrical inner stainless steel ground (or alternatively high voltage)electrode2206, a cylindricalinner dielectric barrier2208 and a cylindrical outer high voltage (or alternatively ground)electrode2210.Cell2202 has aninlet2212 and anoutlet2214 located at thebottom end2216 ofcell2202. The space between the outer diameter ofdielectric barrier2208 and the inner diameter ofhigh voltage electrode2210 forms areaction volume2222 within which gas-liquid mixture1530 is treated.
• Tube1516 is coupled betweenvalve1518 andinlet2212. The interior ofcylindrical ground electrode2202 anddielectric barrier2208 serves as apassageway2220 for delivering gas-liquid mixture1530 (shown in dashed lines) totop end2218 ofNTP cell2202. As gas-liquid mixture1530 exits the top ofpassageway2220, the gas-liquid mixture falls throughreaction volume2222 due to the force of gravity. The treated gas-liquid mixture1530 then exitsoutlet2214 and returns totank1504 throughtube1542. The falling gas-liquid mixture1530 maintains the mixture of gas and liquid and increases the surface area of the liquid that is exposed to the NTP species. This can further increase the effectiveness of the NTP treatment. Alternatively,inlet2212 can be positioned atupper end2218.
• NTP cell2202 further includes acylindrical dielectric film2230, which separatesreaction volume2222 into atreatment region2232 and adischarge initiation region2234.Discharge initiation region2234 can be filled with a gas or a vacuum, as discussed above, and is physically isolated from the gas-liquid mixture being treated inregion2232. In an alternative embodiment,initiation region2234 is positioned betweentreatment region2232 andelectrode2210. Additional discharge initiation regions can also be used, as discussed above.
• FIG. 27 is a cross-sectional view of acylindrical NTP cell2300 according to an alternative of the present invention.FIG. 28 is a cross-sectional view ofNTP cell2300 taken along lines28-28 ofFIG. 27. The same reference numerals are used inFIGS. 27 and 28 as were used inFIG. 26 for the same or similar elements.NTP cell2300 is similar toNTP cell2202, but further includes an outercylindrical dielectric barrier2302 positioned betweenreaction volume2222 and the inner diameter ofouter electrode2210.
• FIG. 29 is a diagram, which schematically illustrates anNTP reactor2500 in which NTP cell2300 (shown inFIGS. 27 and 28) can be used. Again, the same reference numerals are used inFIG. 29 as were used inFIG. 26 for the same or similar elements.
• FIG. 30 is a diagram, which illustrates aconical NTP reactor2600 according to another alternative embodiment of the present invention.Reactor2600 includes aconical NTP cell2600 having a conicalinner electrode2604, a conical inner dielectric barrier2606, a conical outer dielectric barrier2608 and a conical outer electrode2610. The space between the outer diameter of dielectric barrier2606 and the inner diameter of dielectric barrier of2608 defines areaction volume2612 through which gas-liquid mixture1530 passes for treatment.NTP cell2602 has acentral axis2614, which is aligned vertically similar to the NTP cells shown inFIGS. 26-29.Inlet2212 is positioned at the base ofcell2602, and includes apassage2614, which extends through the interior ofconical electrode2604 to the top ofreaction volume2612. In an alternative embodiment,inlet2212 is positioned at the top ofNTP cell2602. Dielectric barriers2606 and2608 isolateelectrodes2604 and2610 from the gas-liquid mixture1530 withinreaction volume2612.
• In alternative embodiments, the cylindrical or conical NTP cells shown inFIGS. 26-30 can further include one or more dielectric films and discharge initiation regions similar to those shown or described with reference toFIGS. 20 and 21. Also, the cylindrical or conical dielectric barriers can be spaced from their respective electrodes to provide one or more discharge initiation regions between the electrodes and dielectric barriers.
• FIG. 31 illustrates anon-thermal plasma reactor2700 in which the liquid is sprayed into the reaction volume, according to another alternative embodiment of the present invention.Reactor2700 has anNTP cell2702, which includes vertically alignedelectrode plates2704 and2706,dielectric barriers2708 and2710 andreaction volume2712. A sprayingnozzle2714 is positioned at atop end2716 ofreaction volume2712 as is coupled tovalve1518 throughtube1528. Sprayingnozzle2714 sprays the liquid1508 throughreaction volume2712, betweendielectric barriers2708 and2710 to form afine mist2718 within the reaction volume. Gravity pulls the liquid droplets inmist2718 downward towardoutlet2720 at which the liquid droplets are returned totank1504.
• Any of the reactor cell structures discussed in the present application can be used in theNTP reactor2700 in alternative embodiments of the present invention.NTP cell2702 can have parallel plate electrodes or concentric cylindrical electrodes, for example, and can have one or more discharge initiator regions as discussed above.
• FIG. 32 is a diagram, which illustrates anNTP reactor2800 according to another alternative embodiment of the present invention. The same reference numerals are used inFIG. 32 as were used inFIG. 31 for the same or similar elements. Similar to the embodiment shown inFIG. 31,NTP reactor2800 includes an NTP cell2802 having vertically alignedelectrode plates2704 and2706,dielectric barriers2708 and2710 andreaction volume2712. In addition, NTP cell2802 includes a pair ofdielectric films2804 and2806, which separatereaction volume2712 fromdielectric barriers2708 and2710, respectively. The space betweendielectric film2804 anddielectric barrier2708 forms adischarge initiation region2808. Similarly, the space betweendielectric film2806 anddielectric barrier2710 forms adischarge initiation region2810.
• NTP cell2802 further includes a thin curtain-formingtube2812, which is coupled totube1528 at thetop end2816 of cell2802. Astube1528 delivers liquid1508 to curtain-formingtube2812, the liquid falling fromtube2812 forms a “curtain”2820 of liquid throughreaction volume2712. The curtain of liquid2820 significantly increases the surface area of the liquid that is exposed to the NTP species and encourages mixing of the liquid with the surrounding gas inreaction volume2712. The treated liquid returns totank1504.Curtain forming tube2812 can include a horizontal tube with holes in the bottom or with overflow openings along the sides of the tube to form the curtain of liquid. Other structures can also be used to form a continuous or intermittent liquid “curtain”.
5. Further Experimental Results
• Further experiments were conducted on animal blood samples using a variety of the further reactor embodiments discussed above, and with various operating conditions. For example in one experiment,NTP system3300 shown inFIG. 33 was used as a test apparatus.System3300 included aliquid source tank3302, apump3302,NTP reactor3306 andpower supply3308.Tube3310 coupledtank3302 to pump3304, andtube3312 coupledpump3304 with an inlet ofreactor3306.Tube3314 coupled an outlet ofreactor3306 withtank3302.
• Reactor3306 had a pair of oppositelypolarized electrodes3320 and3322, which were separated by areaction volume3326.Dielectric barriers3328 and3330 electrically and physicallyisolated electrodes3320 and3322 fromreaction volume3326.Electrodes3320 and3322 had an area of 920 mm×52 mm, and were separated by a discharge gap of 16 mm.Dielectric barriers3328 and3330 had thicknesses of 1.5 mm.
• Pump3304 drew liquid3336 fromtank3302 throughtube3310 and passed the liquid toreaction volume3326 throughtube3312.Tube3314 returned the treated liquid totank3302. The upper surface of liquid3336 inreaction volume3326 is shown by the dashed line. The volume above the dashed line served as a discharge initiation region. In this experiment,reaction volume3326 did not include a membrane for separating the discharge initiation region. Also, a gas injector was not used for creating a liquid-gas mixture. However, other experiments were performed with these additional elements, and achieved positive results.
• During the experiment, three separate tests were performed. For each test a sample of six hundred milliliters (ml) of fresh cow blood was placed intank3302. Each sample included 10 standard units per milliliter (u/ml) of heparin anti-coagulant, and was inoculated withE. coli933 prior to treatment. Each sample had a different total bacteria count.Power supply3308 energizedelectrodes3320 and3322 with an AC voltage of 16-22 kV at a frequency of 60 Hz.Pump3304 passed the sample throughreactor3306 at a flow rate of 250 milliliters per minute (ml/min).
• The samples were treated for up to three hours, which deviated from the experiments discussed above. In those experiments, a shorter treatment time and a higher electric field were used. It was found that when a high electric field (such as 30 kV) was used, the blood samples coagulated very fast, especially along the surface layer of the sample. In the present experiment, lower energy and longer treatment times were used, which were expected to reduce any adverse impacts on the quality of the treated samples.
• Another factor in the present experiment was that the sample was circulated many times throughreactor3306, which inevitably caused recontamination. This, in turn, prolonged the needed treatment time for a given reduction in bacterial count and resulted in unnecessary multiple exposures of the samples to the treatment, which increased potential damage due to the treatment. Although this kind of treatment may not be the most desirable for a practical embodiment, it allowed for a relatively simple and small experimental setup. If re-circulation and re-contamination can be avoided, the treatment time would be substantially reduced. For example, the reactor can be made with a longer reaction path for conducting one-pass experiments.
• a. Inactivation ofEscherichia coli(E. coli)
• The following table shows the level ofE. colibacterial reduction for the present experiment as a function of treatment time for each sample.

  	ORIGINAL	REDUC-	REDUC-	REDUC-
  	BAC-	TION	TION	TION
  	TERIAL	AFTER	AFTER	AFTER
  	COUNT	1HOUR	2HOURS	3HOURS

  SAMPLE

  1	1.1 × 106	75%	99%	99.5%
  SAMPLE
  2	1.76 × 106	86%	98.5%	99.6%
  SAMPLE
  3	6.85 × 105	—	—	99.8%

• FIG. 34 is a graph illustrating bacterial inactivation for each sample as a function of treatment time in hours. These results show that a 3-log reduction ofE. colibacteria inoculated in cow blood can be achieved using the simple test apparatus shown inFIG. 33.
• b. Change in Hematological Properties of Blood Samples
• FIG. 35 is a graph illustrating concentration of blood plasma hemoglobin in the blood samples as a function of treatment time for the apparatus shown inFIG. 33. The concentration of blood plasma hemoglobins increased with treatment time.
• FIG. 36 is a graph illustrating concentration of white blood cells (WBCs) in the blood samples as a function of treatment time, andFIG. 37 is a graph illustrating concentration of red blood cells (RBCs) in the blood samples as a function of treatment time. The white and red blood cell concentrations remained within the normal reference ranges for these properties following treatment.
• FIG. 38 is a graph illustrating concentration of Total Plasma Protein (TPP) in the blood samples as a function of treatment time. The Total Plasma Protein concentration changed very little after treatment, and varied only from 7.2 g/dL to 8.0 g/dL, which is within the normal range of 6.8 g/dL to 9.2 g/dL for cow blood.
• FIG. 39 is a graph illustrating concentration of fibronigen in the blood samples as a function of treatment time. Again, the fibronigen concentration varied within the allowed range, except after three hours of treatment.
• c. Treatment of a Virus
• The test apparatus shown inFIG. 33 was also used successfully to treat a virus in water samples. The water samples contained 5.5×10³units per milliliter of Infection Bovine Rhinotracheitis (IBR) virus. A first water sample was passed throughNTP reactor3306 four times, without being re-circulated through a common tank as inFIG. 33. No virus could be detected in the first water sample after the treatment. A second water sample was circulated through the reactor and acommon tank3302 for a period of 40 minutes. Again, no virus could be detected in the second water sample after the treatment. The NTP treatments were therefore effective for killing the IBR virus, even with very brief treatment as in the case of the first water sample.
• Non-thermal plasma can therefore be used for at least partially disinfecting biological fluids, such as human and animal blood while leaving most of the hematological properties of the blood within normal ranges following treatment. Any adverse affects on these properties can be reduced by further optimization of the system and its operating parameters.
• Since there is substantially no ohmic heating, energy consumption during non-thermal plasma treatment is small, and there is no need to cool the liquid being treated. This allows the system to be easily scaled-up accommodate a very large treatment volume. The desired treatment time can be obtained by passing the liquid through multiple NTP reactors connected together in series with one another, by increasing the reaction volume length, decreasing the flow rate, or by cycling the liquid through the same reactor multiple times. Also, the number of series-connected reaction volumes in the same reactor can be increased or decreased. Because of the non-thermal nature of the system, the system preserves the quality and other heat-sensitive attributes of the liquid. Also, since each electrode is physically and electrically isolated from the liquid being treated, the electrodes do not act as a source of contaminants to the liquids.
• In effect, the non-thermal plasma utilizes several different species to inactivate pathogen, including highly reactive species that stabilize immediately upon removing the electric field, some ozone, ultraviolet, photons, and the like. These species do not appear to lead to unsafe excess concentration levels, which would be the case with exclusive exposure to higher levels of any one of these inactivation mechanisms alone. Although ozone is one of the highly reactive species that is generated, the concentration is more limited and the species are very short-lived as compared to more traditional ozonation systems. Lingering ozone may be an advantage for purifying bottled water, but in biological fluids, control of all biochemical process is critical. Non-thermal plasma species virtually all resolve themselves and lose reactivity immediately upon removal of the electric field, making it essentially totally controllable by the treating medical specialist. This allows non-thermal plasma to be used for more time-sensitive treatments of biological fluids where long time periods are not generally available for reducing excess ozone levels in the treated fluid.
• Non-thermal plasma can therefore be an effective method of disinfecting biologic fluids using processes that are either replacements for or adjunctive to traditional antibiotic and anti-viral therapies. For example, blood or cerebrospinal fluid can be treated with non-thermal plasma to eliminate bacteria such asstaphylococcusor viruses without toxicity to the characteristics of the fluids. Another clinical application would be to couple an NTP system in series with a renal dialyzer. Non-thermal plasma can be used to treat severe blood-borne infections when drugs are not indicated, or to disinfect donated blood in blood bank storage, increasing the usable supplies. Treatment can be performed as the blood is drawn from the donor, at the blood bank, or as the blood is transfused into the receiving patient. It is also possible that non-thermal plasma can potentially be used as an adjunctive (supporting) therapy to assist with the treatment of bacterial meningitis, where there is a need to stay ahead of the rapid bacterial reproduction and spread without poisoning the patient with the bacterial toxins.
• Further examples of possible non-thermal plasma treatments include: 1) treatment of peritonitis (quasi-dialyzing by injecting sterile water or other dialysate compositions into the peritoneal cavity and cycling the water through an endoscope or catheter having an associated internal or external NTP reactor); 2) treatment of Septicemia (e.g., by coupling an NTP reactor in series with a hemodialysis apparatus); 3) treatment of a liver or gall bladder abcess endoscopically, such as by cycling bile, etc. through a lumen in the endoscope and treating the bile with non-thermal plasma; 4) treating hepatitis by injecting sterile saline or other fluidic agents into the liver and processing liver fluids in vivo with non-thermal plasma; 5) treating viral or bacterial meningitis; and 6) treating lymph by processing the lymph with non-thermal plasma and feeding it back into the bloodstream through the thoracic duct, for example. Numerous other applications exist.
• For example, when blood is treated using the hemodialysis-type blood pasteurization system described byFIGS. 2, 18 and42, for example, which could utilize any of the different described NTP reactor chambers, in conjunction with the other circulating and filtering mechanisms shown, the blood is diluted for improved flow and clotting resistance. After treatment, the diluted blood is applied to a semi-permeable membrane having openings for filtering-out the diluent, common blood-born bacteria and/or other toxins in the blood, as described in more detail with respect toFIGS. 18 and 42.
• Non-thermal plasma can also be used in conjunction with a single, double or triple lumen probe or catheter, for example, with non-thermal plasma electrodes on the distal end or positioned along one or more of the lumens. These probes can be inserted endoscopically into a diseased organ, an artery or vessel, for example, and local fluids can be treated with non-thermal plasma by positioning the electrode adjacent the area in the body to be treated or by pumping bodily fluids through reaction volume within a lumen to destroy undesirable elements, in place of open surgery. The electrodes can be placed directly on inflamed tissue to shower the tissue with reactive species (e.g., oxygenated radicals, etc.) while they are still reactive. For example, a surface non-thermal plasma electrode (with alternating-polarity conductors along its surface) can be used to generate a surface non-thermal plasma that can be used to treat the tissue. This surface non-thermal plasma electrode can be positioned on the distal end of an instrument, for example, which is inserted into the body. Other structures and treatment methods can also be used.
• FIG. 40 is a diagram, which schematically illustrates anelongated probe4000 that can be used for in-vivo NTP treatment according to one embodiment of the present invention. The shaft can include any medical instrument, catheter or endoscope-type device, with or without an internal lumen, which can be used to access an internal cavity, such as the interior of a hollow organ or lumen, of a mammal. In this example,probe4000 includes aproximal end4002, adistal end4004, anNTP reactor4006 carried along the shaft, and apump4008. When the shaft ofprobe4000 is inserted into an organ, artery or other region of a patient,pump4008 draws fluid frominlet4010 and passes the fluid throughNTP reactor4006 tooutlet4012. The treated fluid is then returned to the patient fromoutlet4012.Inlet4010 andoutlet4012 can be positioned anywhere alongprobe4000, and the particular arrangement would depend on the procedure being performed and the desired flow pattern into and out of the shaft. Similarly,NTP reactor4006 and pump4008 can be positioned anywhere on or inprobe4000 or external toshaft4000. Also, pump4008 can be positioned anywhere along the fluid travel path betweeninlet4010 andoutlet4012.Probe4000 can be a stand-alone device for NTP treatment or can be combined with the function of another medical instrument.Probe4000 can have one or more lumens for passing the fluid to be treated and can have additional lumens or elements as desired.
• FIG. 41 is a diagram, which schematically illustrates aprobe4100 that can be used for in-vivo NTP treatment according to another embodiment of the present invention in which no pump is needed.Probe4100 includes a shaft with aproximal end4102, adistal end4104 and anNTP reactor4106. Similar to the embodiment shown inFIG. 16, for example,reactor4106 includes oppositely polarizedelectrodes4108 and4110, adischarge initiation region4112, atreatment region4114 and aseparating film4116. However,electrode4110 is formed of a wire mesh, which is supported on the distal end of the shaft by one ormore support beams4118, for example, to promote the flow of fluid into and out oftreatment region4114. With this structure, the perimeter oftreatment region4114 is open to an exterior ofprobe4100.Electrode4110 can be bare conductive material or coated with a dielectric material, for example.Film4116 isolatesdischarge initiation region4112 fromtreatment region4114. In one embodiment,discharge initiation region4112 is bounded byelectrode4108,film4116 and the sidewall ofprobe4100. Fluid enteringtreatment region4114 is exposed to the NTP species generated acrosstreatment region4114 and those species that are generated ininitiation region4112 and pass throughfilm4116. During treatment, thedistal end4104 ofprobe4100 can be moved in and around the area of the body to be treated. For example, the distal tip can be swept through a locally infected area such as a liver, lung, or abdomen for killing sufficient concentrated pathogens to reduce the viral load to a level that is within the body's immune system capacity. Such an instrument could also process blood flowing into the vena cava from the lymph system.
• Numerous other instrument structures can be used for facilitating in-vivo NTP treatment in further alternative embodiments of the present invention. The fact that the NTP species only remain active during roughly the time when the electrical field is powered can help to limit adverse effects of the treatment.
• FIG. 42 is a diagram illustrating one system andmethod4200 for ex-vivo disinfecting blood of a live human or animal patient using non-thermal plasma according to another embodiment of the present invention.System4200 is a circulating ex-vivo hemodialysis-type of apparatus, which draws blood from the circulatory system of alive patent4201 through one or more arteries, for example, treats the blood with non-thermal plasma and returns the disinfected blood to the patient. The NTP system can achieve substantial reduction in bacterial or viral loads with fewer attendant complications, such as clotting, excess destruction of desired blood fractions, antibiotic resistance, etc. This ex vivo blood treatment could filter out bacterial toxins released before returning the blood to the body because of the disparity in size between bacteria and its products, and the essential solid blood fractions. After treatment, any additional required fluids and lipids can be provided via intravenous (I.V.) application.
• NTP system4200 includes ablood pump4202 for drawing blood from patient4201 through ashunt4204 and atube4206. An arterial pressure monitor4208 can be coupled to tube5206 for monitoring pressure within the patient's circulatory system during the procedure. Afurther pump4210 pumps the blood drawn from patient4201 byblood pump4202 to areservoir tank4212 throughtubes4214 and4216. In one embodiment, a temperature-conditioneddiluent4220 is added to the blood alongtube4214 until the blood is translucent, for example. Diluent4220 can include sterile water, an anti-coagulant (such as heparin) and other elements as needed.Reservoir tank4212 stores the diluted blood for treatment. The diluent makes the fluid less opaque so that photons generated inreactor4230 can have better effect, and also improves the flow characteristics and reduces potential clotting levels within the apparatus.
• The diluted blood passes fromtank4212 toNTP reactor4230 through tube4232 andgas injector4234.Gas injector4234 injects a gas into the diluted blood as described above with respect toFIGS. 2 and 3, for example.NTP reactor4230 can have any suitable structure. In one embodiment,NTP reactor4230 is similar toreactor1600 shown inFIG. 22, which has separate treatment and discharge initiation regions. The treatment region ofNTP reactor4230 can have multiple parallel paths for the diluted gas-blood mixture to optimize throughput and can have consecutive chambers to increase disinfection in each cycle. As many consecutive chambers can be used as are safe and efficacious.NTP reactor4230 is driven by a continuousA.C. power supply4236 having an output voltage of 5 kV to 35 kV and a frequency of 1 Hz to 1000 Hz, for example, to generate cool non-thermal plasma as the diluted gas-blood mixture passes through the reactor.
• After NTP treatment application byreactor4230, the diluted gas-blood mixture is filtered to remove the diluent and the physically small toxin molecules while preserving the red and white blood cells and other beneficial blood components. For example, the diluted gas-blood mixture can be pumped under pressure throughtube4240 and past a semi-permeable membrane withinfilter4242. The membrane passes some of the diluent, which carries with it small particles such as bacteria and toxic protein molecules but not all blood plasma and not the larger molecules such as erythrocytes, leukocytes, platelets, etc. The pore size and other characteristics of the membrane can be selected as desired for the particular procedure being performed. In one embodiment, the pores range in size from 0.1 to 2 micrometers, for example, which are capable of passing the most common blood-borne bacteria.Staphylococcusmolecules are spherically-shaped, and about 0.75 micrometers in size, whileE-coliare elongated “rounded cylinders” about 0.5 micrometers in diameter by 2 micrometers in length. The toxin proteins and other molecules they release upon cell lysis are much smaller, allowing passage through the filter spaces in the membrane. Solid blood fractions, on the other hand, are much larger than bacteria or proteins: RBCs (erythrocytes) are 6-8 microns in diameter, and WBCs range in size from 6 to 16 microns, preventing them from passing through with the waste and excess water. Some platelets, sized between 1 and 4 microns, may be lost with the excess water and toxic waste, but most will be retained. The optimal opening size can be determined based on desired final treated blood composition.
• After filtering, the blood can then be tested for pathogen concentration and either membrane-filtered again or passed tode-aeration module4244 for removing the gas from the gas-blood mixture.
• The de-gassed, re-concentrated blood can then be returned to the patient's body. In one embodiment, the de-gassed, re-concentrated blood first passes through agas detector4250 andvenous pressure monitor4252 before being returned to a vein of patient4201 through a shunt5254 and atube4256. If any gas remains in the blood, clamp5258 can be closed automatically to prevent the gas from being delivered to the patient. Also,clamp4258 can be used to maintain a desired venous pressure withinpatient4201 as measured by monitor5252. As the blood is returned to the body, it can also be tested for electrolyte and lipid levels and those levels enhanced as needed.
• The process shown inFIG. 42 can involve multiple chambers inreactor4230 or multiple passes through the body and back throughsystem4200 as to best cleanse the blood.System4200 can have various arrangements and elements in alternative embodiments of the present invention. The gas composition, level of dilution, and flow rates can be traded off with electric field strength to optimize the system performance with regard to time, pathogen kill-rate, and patient tolerance of the process.
• A variety of diseases or pathogens could be treated with NTP using an apparatus similar to those discussed herein or modified to suit the particular treatment. These diseases include any fluid-borne pathogen that can be destroyed with non-thermal plasma generated by one or more electrodes that are electrically isolated from the treated liquid by a dielectric. Different types of gasses can be introduced to the liquid being treated through the gas source (e.g., bubbler or gas injector), depending on desired inactivation effect (target pathogen). In some embodiments, the liquid being treated is not mixed with a gas. Also, certain selected human or other animal blood characteristics can be modified as desired through the use of NTP, such as the variance of white blood cell count.
• In addition, embodiments of the present invention provide a pasteurization process that is able to cycle fluids such as blood through an apparatus outside the body to destroy bacterial infection, filter out the toxins released in the process, and then return the cleansed biologic fluid back to the patient in a process that is reasonably compatible with circulatory system time cycles. This process has the potential to provide significant anti-infective benefit, whether as a primary therapy or as an adjuvant supporting treatment used in conjunction with modified dosages of drugs or in cases where the patient's immune system cannot tolerate the bacterial toxin releases that accompany drug therapy.
• Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.

Claims (21)

1. A method of at least partially disinfecting biological fluid of a mammal, which comprises pathogens, the method comprising:

(a) drawing the biological fluid from the mammal;

(b) contacting a non-thermal plasma with the biological fluid to kill at least a portion of the pathogens within the biological fluid;

(c) filtering toxins from at least some components of the biological fluid after contacting in step (b); and

(d) returning the biological fluid to the mammal after filtering the toxins in step (c).

2. The method ofclaim 1 wherein:

step (a) comprises drawing the biological fluid from a blood circulatory system of the mammal; and

step (d) comprises returning the biological fluid to the blood circulatory system.

3. The method ofclaim 1 wherein:

step (a) comprises drawing the biological fluid from an organ of the mammal; and

step (d) comprises returning the biological fluid to the organ.

4. The method ofclaim 1 and further comprising:

(e) introducing gas bubbles into the biological fluid to generate liquid-gas mixture; and

(f) contacting the liquid-gas mixture with the non-thermal plasma during step (b).

5. The method ofclaim 4 and further comprising:

(g) removing the gas bubbles from the liquid-gas mixture after contacting in step (b) and before returning in step (d).

6. The method ofclaim 5 and further comprising:

(h) passing the biological fluid through a gas detector after step (g) and prior to returning the biological fluid to the mammal in step (d).

7. The method ofclaim 1 and further comprising:

(e) introducing a diluent into the biological fluid to generate a diluted biological fluid; and

(f) treating the diluted biological fluid with the non-thermal plasma during step (b); and

(g) filtering some of the diluent from the diluted biological fluid in step (c).

8. The method ofclaim 1 wherein step (c) comprises passing the biological fluid along a semi-permeable membrane having pore sizes that filter toxins having selected sizes from larger components of the biological fluid.

9. The method ofclaim 8 wherein the semi-permeable membrane comprises pore sizes of approximately 0.1 to 2 micrometers.

10. The method ofclaim 1 wherein step (c) comprises filtering at least some blood-borne bacteria from at least some components of the biological fluid.

11. A method of at least partially disinfecting biological fluid of a mammal, which comprises pathogens, the method comprising:

(a) contacting a non-thermal plasma with the biological fluid to kill at least a portion of the pathogens within the biological fluid; and

(b) filtering toxins from at least some components of the biological fluid after contacting in step (a).

12. The method ofclaim 11 wherein:

step (a) releases toxins from at least some of the pathogens; and

step (b) comprises filtering the toxins released in step (a) from at least some components of the biological fluid.

13. The method ofclaim 11 wherein step (b) comprises passing the biological fluid along a semi-permeable membrane having pore sizes that filter toxins having selected sizes from larger components of the biological fluid.

14. The method ofclaim 13 wherein the semi-permeable membrane comprises pore sizes of approximately 0.1 to 2 micrometers.

15. The method ofclaim 11 wherein step (b) comprises filtering at least some blood-borne bacteria from at least some components of the biological fluid.

16. The method ofclaim 11 and further comprising:

(c) drawing the biological fluid from the mammal prior to step (a); and

(d) returning the biological fluid to the mammal after filtering the toxins in step (b).

17. The method ofclaim 16 wherein:

step (c) comprises drawing the biological fluid from a blood circulatory system of the mammal; and

step (d) comprises returning the biological fluid to the blood circulatory system.

18. The method ofclaim 16 wherein:

step (c) comprises drawing the biological fluid from an organ of the mammal; and

step (d) comprises returning the biological fluid to the organ.

19. The method ofclaim 11 and further comprising:

(c) introducing gas bubbles into the biological fluid to generate liquid-gas mixture prior to step (a);

(d) contacting the liquid-gas mixture with the non-thermal plasma during step (a); and

(e) removing the gas bubbles from the liquid-gas mixture after contacting in step (a).

20. The method ofclaim 11 and further comprising:

(c) introducing a diluent into the biological fluid to generate a diluted biological fluid;

(d) treating the diluted biological fluid with the non-thermal plasma during step (a); and

(e) filtering some of the diluent from the diluted biological fluid in step (b).

21. A liquid-gas mixture comprising a mammalian biological liquid, gas bubbles, and a non-thermal plasma.

Images